Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
LCP
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"
Image for the paper "Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients"

Cancer and coronavirus

Mathematical medicine

Cancer patients who contract and recover from Coronavirus-2 exhibit long-term immune system weaknesses, depending on the type of cancer.

Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

Cancer Cell 39, 261 (2021)

S. A. Jawad, L. Baú, T. Alaguthurai, I. del Molino del Barrio, A. G. Laing, T. S. Hayday, L. Monin, M. Muneoz-Ruiz, L. McDonald, I. F. Quijorna, D. McKenzie, R. Davis, A. Lorenc, J. Nuo En Chan, S. Ryan, E. Bugallo-Blanco, R. Yorke, S. Kamdar, M. Fish, I. Zlatareva, P. Vantourout, A. Jennings, S. Gee, K. Doores, K. Bailey, S. Hazell, J. De Naurois, Ch. Moss, B. Russell, A. A. Khan, M. Rowley, R. Benjamin, D. Enting, D. Alrifai, Y. Wu, Y. Zhou

Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19+ non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.

Cancer Cell 39, 261 (2021)

S. A. Jawad, L. Baú, T. Alaguthurai, I. del Molino del Barrio, A. G. Laing, T. S. Hayday, L. Monin, M. Muneoz-Ruiz, L. McDonald, I. F. Quijorna, D. McKenzie, R. Davis, A. Lorenc, J. Nuo En Chan, S. Ryan, E. Bugallo-Blanco, R. Yorke, S. Kamdar, M. Fish, I. Zlatareva, P. Vantourout, A. Jennings, S. Gee, K. Doores, K. Bailey, S. Hazell, J. De Naurois, Ch. Moss, B. Russell, A. A. Khan, M. Rowley, R. Benjamin, D. Enting, D. Alrifai, Y. Wu, Y. Zhou